Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
SILK

SILK - Silk Road Medical Inc Stock Price, Fair Value and News

26.88USD+5.21 (+24.04%)Market Closed

Market Summary

SILK
USD26.88+5.21
Market Closed
24.04%

SILK Alerts

  • Losses in recent quarter

SILK Stock Price

View Fullscreen

SILK RSI Chart

SILK Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-19.85

Price/Sales (Trailing)

5.72

Price/Free Cashflow

-28.81

SILK Price/Sales (Trailing)

SILK Profitability

Return on Equity

-36.27%

Return on Assets

-21.17%

Free Cashflow Yield

-3.47%

SILK Fundamentals

SILK Revenue

Revenue (TTM)

185.5M

Rev. Growth (Yr)

20.81%

Rev. Growth (Qtr)

2.57%

SILK Earnings

Earnings (TTM)

-53.4M

Earnings Growth (Yr)

14.12%

Earnings Growth (Qtr)

-8.65%

Breaking Down SILK Revenue

Last 7 days

21.3%

Last 30 days

21.2%

Last 90 days

41.6%

Trailing 12 Months

-15.9%

How does SILK drawdown profile look like?

SILK Financial Health

Current Ratio

11.05

Debt/Equity

0.52

Debt/Cashflow

-0.46

SILK Investor Care

Shares Dilution (1Y)

1.85%

Diluted EPS (TTM)

-1.38

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024185.5M000
2023150.7M162.9M169.9M177.1M
2022107.4M114.2M126.8M138.6M
202178.3M89.7M94.3M101.5M
202069.5M69.7M72.7M75.2M
201941.6M48.8M56.2M63.4M
201819.3M24.4M29.5M34.6M
201700014.3M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Silk Road Medical Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 05, 2024
klemz kevin m
sold
-42,871
17.169
-2,497
evp/chief legal officer/sec.
Mar 05, 2024
ruedy richard
sold
-65,242
17.169
-3,800
evpclin&reg.affairs&qa
Mar 05, 2024
buchanan lucas w.
sold
-169,578
17.169
-9,877
coo/cfo
Mar 05, 2024
ballinger kevin j.
bought
198,783
16.99
11,700
-
Mar 05, 2024
davis andrew s.
sold
-94,103
17.169
-5,481
chief commercial officer
Mar 05, 2024
jones marie l.
sold
-44,673
17.169
-2,602
vp, finance and cao
Mar 01, 2024
klemz kevin m
acquired
-
-
42,818
evp/chief legal officer/sec.
Mar 01, 2024
mckhann chas
acquired
-
-
110,313
chief executive officer
Mar 01, 2024
davis andrew s.
acquired
-
-
62,201
chief commercial officer
Mar 01, 2024
buchanan lucas w.
acquired
-
-
74,954
coo/cfo

1–10 of 50

Which funds bought or sold SILK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
unchanged
-
609
1,652
-%
May 24, 2024
Cetera Investment Advisers
new
-
755,883
755,883
-%
May 16, 2024
COMERICA BANK
unchanged
-
260
788
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.91
-6,820
70,788
-%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-3,018,060
-
-%
May 15, 2024
TWO SIGMA INVESTMENTS, LP
added
35.75
7,406,230
14,619,100
0.03%
May 15, 2024
B. Metzler seel. Sohn & Co. AG
added
13.67
219,528
534,413
0.01%
May 15, 2024
QUADRANT CAPITAL GROUP LLC
unchanged
-
3,140
9,509
-%
May 15, 2024
Voya Investment Management LLC
reduced
-18.75
40,442
230,136
-%
May 15, 2024
Point72 Asia (Singapore) Pte. Ltd.
new
-
65,134
65,134
0.02%

1–10 of 43

Are Funds Buying or Selling SILK?

Are funds buying SILK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SILK
No. of Funds

Unveiling Silk Road Medical Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
7.43%
2,891,769
SC 13G/A
Feb 09, 2024
wasatch advisors lp
-
0
SC 13G/A
Feb 05, 2024
goldman sachs group inc
5.8%
2,277,063
SC 13G
Jan 26, 2024
blackrock inc.
7.7%
3,012,320
SC 13G/A
Oct 20, 2023
flynn james e
0.00%
0
SC 13G
Aug 10, 2023
alliancebernstein l.p.
0.1%
46,800
SC 13G/A
May 10, 2023
wasatch advisors lp
-
0
SC 13G/A
Feb 14, 2023
alliancebernstein l.p.
6.9%
2,616,795
SC 13G/A
Feb 13, 2023
capital world investors
7.8%
2,966,730
SC 13G/A
Feb 10, 2023
flynn james e
3.66%
1,396,640
SC 13G/A

Recent SEC filings of Silk Road Medical Inc

View All Filings
Date Filed Form Type Document
Jun 18, 2024
DEFA14A
DEFA14A
Jun 18, 2024
DEFA14A
DEFA14A
Jun 18, 2024
DEFA14A
DEFA14A
Jun 18, 2024
DEFA14A
DEFA14A
Jun 18, 2024
DEFA14A
DEFA14A
Jun 18, 2024
8-K
Current Report
May 30, 2024
SD
SD
May 07, 2024
10-Q
Quarterly Report
Apr 30, 2024
8-K
Current Report
Apr 26, 2024
DEFA14A
DEFA14A

Peers (Alternatives to Silk Road Medical Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.0B
40.3B
-0.10% -2.08%
32.14
4.49
-2.84% -3.00%
67.6B
19.7B
-1.04% -9.58%
50.7
3.43
4.82% -17.56%
18.2B
3.9B
-10.79% -26.67%
39.44
4.66
5.72% 46.72%
17.2B
14.9B
-4.26% -25.60%
6.49
1.15
2.98% 207.68%
MID-CAP
9.7B
3.5B
-0.60% 25.29%
31.07
2.74
6.16% 35.06%
8.7B
12.4B
-8.47% -12.48%
22.53
0.7
-0.93% -18.83%
8.2B
2.6B
-1.69% -23.28%
-25.56
3.16
-6.25% -68.58%
5.3B
3.9B
-9.26% -35.41%
-55.79
1.35
0.23% 90.80%
3.4B
387.1M
-0.06% 30.91%
-216.17
8.9
30.82% 65.57%
2.2B
6.6B
-1.48% -10.95%
12.01
0.34
1.50% -10.29%
SMALL-CAP
1.5B
3.2B
12.63% 11.29%
-2.15
0.46
7.94% -1695.32%
384.5M
169.3M
2.09% -2.41%
-5
2.27
7.49% -244.90%
226.3M
324.0M
-6.46% -49.01%
-1.18
0.7
-3.19% -337.41%
47.1M
50.5M
-15.62% -80.60%
-2.07
0.93
14.25% -10.06%
1.8M
3.7M
70.00% -81.62%
-0.15
0.48
5.77% 8.23%

Silk Road Medical Inc News

Latest updates
Yahoo Finance4 hours ago

Silk Road Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue2.6%48,484,00047,270,00044,435,00045,298,00040,131,00040,070,50037,374,00033,173,00028,021,00028,265,00024,701,00026,456,00022,053,00021,133,00020,067,00015,094,00018,933,00018,634,00017,026,00014,928,00012,766,000
Gross Profit4.9%36,501,00034,802,00032,385,00032,294,00027,605,00029,091,50028,066,00024,161,00019,444,00021,031,50018,625,00019,858,00016,515,00015,916,00014,579,0009,758,00013,683,00013,913,00012,856,00011,231,0009,427,000
Operating Expenses4.6%51,435,00049,175,00046,056,00046,610,00044,515,00041,721,50037,292,00038,355,00035,398,00035,093,50031,916,00029,810,00026,678,00030,909,50023,913,00019,151,00022,823,00021,420,00020,251,00017,248,00016,573,000
  S&GA Expenses4.3%40,775,00039,111,00036,009,00035,830,00034,082,00032,521,50028,821,00027,700,00027,275,00027,595,00025,049,00022,549,00021,194,00020,872,00019,202,00015,758,00019,692,00018,155,50017,064,00014,135,00013,866,000
  R&D Expenses5.9%10,660,00010,064,00010,047,00010,780,00010,433,0009,200,0008,471,00010,655,0008,123,0007,498,5006,867,0007,261,0005,484,00010,037,5004,711,0003,393,0003,131,0003,264,5003,187,0003,113,0002,707,000
EBITDA Margin---------0.41-0.44-0.47---0.55-0.56-0.64-0.67-0.67-0.74-0.57-0.66-0.78
Interest Expenses-0.7%1,721,0001,734,0001,732,0001,712,0001,693,0001,732,0001,714,0001,031,000621,000634,000633,000628,000623,000791,0001,215,0001,203,0001,202,0001,216,5001,176,0001,207,0001,352,000
EBT Margin---------0.44-0.46-0.49---0.60-0.63-0.72-0.75-0.75-0.83-0.67-0.77-0.90
Net Income-8.6%-14,136,000-13,011,000-12,788,000-13,484,000-16,460,000-12,614,000-10,319,000-15,398,000-16,679,000-14,693,000-13,885,000-10,539,000-10,694,000-16,756,000-10,315,000-10,353,000-9,941,000-8,291,000-8,007,000-11,959,000-24,158,000
Net Income Margin8.5%-0.29-0.31-0.33-0.32-0.36-0.40-0.45-0.53-0.52-0.49-0.55-0.54---------
Free Cashflow-76.4%-15,710,000-8,906,000-7,131,000-5,050,000-12,434,000-4,291,000-5,115,000-11,383,000-16,797,000-14,184,000-7,627,000-9,843,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-4.9%25226526126326027016316314315716616817017918418812713713914339.00
  Current Assets-2.1%23624124123323025514714712814315415916417317818112011213213629.00
    Cash Equivalents12.0%23.0020.0029.0028.0051.0056.0051.0088.0094.0011010610295.0070.0063.0074.0028.0039.0011311916.00
  Inventory2.0%30.0030.0022.0019.0017.0019.0020.0018.0018.0018.0016.0013.0012.0010.0011.0012.0012.0010.009.009.008.00
  Net PPE-0.4%8.008.008.009.009.009.0010.0010.0010.008.005.003.003.003.003.003.003.003.003.003.003.00
Liabilities-8.0%10511410810810210610510375.0077.0077.0072.0069.0072.0064.0060.0063.0066.0061.0058.0091.00
  Current Liabilities-29.5%21.0030.0024.0024.0021.0024.0024.0021.0029.0026.0021.0017.0016.0020.0015.0012.0014.0017.0012.009.0011.00
  Short Term Borrowings---------10.004.00-----------
  Long Term Debt0.3%76.0076.0075.0075.0075.0075.0074.0074.0039.0045.0049.0049.0049.0049.0045.0045.0045.0045.0045.0045.0045.00
    LT Debt, Non Current0.3%76.0076.0075.0075.0075.0075.0074.0074.0039.0045.0049.0049.0049.0049.0045.0045.0045.0045.0045.0045.0045.00
Shareholder's Equity-2.6%14715115315615816457.0060.0068.0079.0088.0096.0010110812012764.0072.0077.0084.00-
  Retained Earnings-3.5%-413-399-386-373-360-343-331-320-305-288-274-260-249-238-222-211-201-191-183-175-163
  Additional Paid-In Capital1.9%5615505405295185083883813733683623563513463423392652632612605.00
Shares Outstanding0.7%39.0039.0039.0039.0039.0038.0035.0035.0035.0035.0035.0034.00---------
Float----1,200---1,300---1,600---1,400-----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-81.3%-15,322-8,453-6,798-4,616-12,147-2,724-4,726-10,406-14,725-11,432-6,495-9,036-11,972-14,269-4,423-11,581-11,795-5,261-6,346-9,383-8,620
  Share Based Compensation7.8%10,3599,60910,24710,1998,8387,5456,3396,1614,9783,9843,6863,4093,5332,2732,0061,6541,293954924837262
Cashflow From Investing1222.8%17,741-1,5807,456-19,1586,106-104,951-32,895-22,150-2,07214,2507,96814,19336,23312,898-7,386-14,797-108-69,619-131-89.00-117
Cashflow From Financing-100.0%-1,0551301,5921,110111,7271,21326,5911681,7712,2422,1178488,36983572,2682741,784507112,210-744
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SILK Income Statement

2024-03-31
Condensed Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Condensed Statements of Operations and Comprehensive Loss [Abstract]  
Revenue$ 48,484$ 40,131
Cost of goods sold11,98312,526
Gross profit36,50127,605
Operating expenses:  
Research and development10,66010,433
Selling, general and administrative40,77534,082
Total operating expenses51,43544,515
Loss from operations(14,934)(16,910)
Interest income2,4712,287
Interest expense(1,721)(1,693)
Other income (expense), net48(144)
Net loss(14,136)(16,460)
Other comprehensive income (loss):  
Unrealized gain (loss) on investments, net(89)249
Other comprehensive income (loss)(89)249
Comprehensive loss$ (14,225)$ (16,211)
Net loss per share, basic$ (0.36)$ (0.43)
Net loss per share, diluted$ (0.36)$ (0.43)
Weighted average common shares used to compute net loss per share, basic39,261,49638,532,202
Weighted average common shares used to compute net loss per share, diluted39,261,49638,532,202

SILK Balance Sheet

2024-03-31
Condensed Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 22,629$ 20,210
Short-term investments151,833161,264
Accounts receivable, net27,20323,573
Inventories30,48629,876
Prepaid expenses and other current assets3,5435,912
Total current assets235,694240,835
Long-term investments2,0279,456
Property and equipment, net8,0858,114
Other non-current assets6,5086,904
Total assets252,314265,309
Current liabilities:  
Accounts payable2,9665,676
Accrued liabilities18,37124,607
Total current liabilities21,33730,283
Long-term debt75,88675,626
Other liabilities7,8068,249
Total liabilities105,029114,158
Commitments and contingencies (Note 7)
Stockholders' equity:  
Preferred stock, $0.001 par value Shares authorized: 5,000,000 at March 31, 2024 and December 31, 2023 Shares issued and outstanding: none at March 31, 2024 and December 31, 2023
Common stock, $0.001 par value Shares authorized: 100,000,000 at March 31, 2024 and December 31, 2023 Shares issued and outstanding: 39,436,634 and 39,165,481 at March 31, 2024 and December 31, 2023, respectively3939
Additional paid-in capital560,854550,495
Accumulated other comprehensive income (loss)(17)72
Accumulated deficit(413,591)(399,455)
Total stockholders’ equity147,285151,151
Total liabilities and stockholders’ equity$ 252,314$ 265,309
SILK
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a specialty balloon for the TCAR procedure. Silk Road Medical, Inc. was incorporated in 2007 and is headquartered in Sunnyvale, California.
 CEO
 WEBSITEhttps://silkroadmed.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES414

Silk Road Medical Inc Frequently Asked Questions


What is the ticker symbol for Silk Road Medical Inc? What does SILK stand for in stocks?

SILK is the stock ticker symbol of Silk Road Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Silk Road Medical Inc (SILK)?

As of Tue Jun 18 2024, market cap of Silk Road Medical Inc is 1.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SILK stock?

You can check SILK's fair value in chart for subscribers.

What is the fair value of SILK stock?

You can check SILK's fair value in chart for subscribers. The fair value of Silk Road Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Silk Road Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SILK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Silk Road Medical Inc a good stock to buy?

The fair value guage provides a quick view whether SILK is over valued or under valued. Whether Silk Road Medical Inc is cheap or expensive depends on the assumptions which impact Silk Road Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SILK.

What is Silk Road Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, SILK's PE ratio (Price to Earnings) is -19.84 and Price to Sales (PS) ratio is 5.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SILK PE ratio will change depending on the future growth rate expectations of investors.